CommercialCoverageMedium impact
08.01.35i, Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Jan 1, 2025
We identified it
Jun 19, 2026
Summary
The medical necessity criteria for Rylaze® (asparaginase Erwinia chrysanthemi) has been updated for commercial insurance plans. This affects coverage requirements for this specialty oncology medication used primarily in cancer treatment protocols.
Action Required
By January 1, 2025: Billing team and oncology providers must review updated medical necessity criteria for Rylaze® prior to prescribing or billing. Ensure all documentation meets new criteria requirements before submitting claims to avoid denials. Update prior authorization workflows if applicable.